Pinteon Therapeutics Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 8

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $25.1M

  • Investors
  • 2

Pinteon Therapeutics General Information

Description

Developer of a novel antibody intended to maintain the brain health of the patients. The company's antibody interrupts the spread of toxic tau and protects and preserves brain function in patients suffering from neurodegenerative disease, enabling doctors to normalize aberrant disease processes and improve patient outcomes in these high unmet medical needs indications.

Contact Information

Website
www.pinteon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1188 Centre Street
  • Newton, MA 02459
  • United States
+1 (917) 000-0000

Pinteon Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pinteon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 11-Jan-2022 $25.1M 000.00 000.00 Completed Generating Revenue
2. Grant 17-Jun-2021 000 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 31-Oct-2019 $17M $17M 0000 Completed Generating Revenue
To view Pinteon Therapeutics’s complete valuation and funding history, request access »

Pinteon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Pinteon Therapeutics’s complete cap table history, request access »

Pinteon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel antibody intended to maintain the brain health of the patients. The company's antibody interrupts t
Drug Discovery
Newton, MA
8 As of 2023
000.00
00.00 0000-00-00
00000000000 000.00

000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
0000 000000000
Cambridge, MA
00 As of 0000
00000
000000&0 00000

000000

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud ex
0000 000000000
South San Francisco, CA
0 As of 0000
00000
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pinteon Therapeutics Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AavantiBio Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 0 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
000 000000000000 Venture Capital-Backed Durham, NC 00 000.00 00000000000 000.00
00000000 Formerly VC-backed San Carlos, CA 00 000.00 000000&0 000.00
You’re viewing 5 of 51 competitors. Get the full list »

Pinteon Therapeutics Patents

Pinteon Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018364630-A1 Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies Pending 09-Nov-2017 000000000
EP-3706795-A4 Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies Pending 09-Nov-2017 000000000 0
US-20200362022-A1 Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies Pending 09-Nov-2017 000000000
CA-3082365-A1 Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies Pending 09-Nov-2017 000000000
EP-3706795-A2 Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies Pending 09-Nov-2017 C07K16/18
To view Pinteon Therapeutics’s complete patent history, request access »

Pinteon Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Martin Jefson Ph.D Chief Executive Officer, President and Board Member
Michael Ahlijanian Ph.D Chief Scientific Officer
Larry Altstiel Ph.D Chief Medical Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Pinteon Therapeutics Board Members (4)

Name Representing Role Since
Jason Dinges Ph.D Morningside Group Board Member 000 0000
Jeffrey Ives Ph.D Self Chairman 000 0000
Justin Burns Ph.D Self Board Member 000 0000
Westley Nolin Ph.D Self Board Member 000 0000
To view Pinteon Therapeutics’s complete board members history, request access »

Pinteon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pinteon Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Advanced Technology International Corporation 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
To view Pinteon Therapeutics’s complete investors history, request access »